NCT04914247|Unknown
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
2 other identifiers
CR10866967896049PAH4002
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredJun 2021
Brief Summary
The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 31, 2021
Completed4 days until next milestone
First Posted
Study publicly available on registry
June 4, 2021
CompletedLast Updated
March 27, 2026
Status Verified
March 1, 2026
First QC Date
May 31, 2021
Last Update Submit
March 24, 2026
Conditions
Interventions
SelexipagDRUG
Sponsors & Collaborators
- Actelionlead
MeSH Terms
Conditions
Thromboangiitis Obliterans
Interventions
selexipag
Condition Hierarchy (Ancestors)
Arterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesVasculitis
Study Officials
- STUDY DIRECTOR
Actelion Clinical Trial
Actelion
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 31, 2021
First Posted
June 4, 2021
Last Updated
March 27, 2026
Record last verified: 2026-03